Overview
Waldenström macroglobulinemia (WM) is a rare B-cell lymphoma in which abnormal lymphoplasmacytic cells build up in the bone marrow and produce excess IgM antibody. Many patients are treated with ibrutinib, a BTK inhibitor that blocks a key survival pathway in these cancer cells. Although ibrutinib is often effective, responses vary widely: some patients achieve durable disease control, while others develop resistance or progress during treatment.
This study explored why those differences happen. Using a prospective phase 2 trial of ibrutinib in previously untreated WM, the investigators followed tumor and immune cells over time with single-cell multiomics, a technology that can measure genetic and transcriptional changes in individual cells. The work provides a detailed view of how tumor subclones evolve and how T cells change during therapy.
Why this study matters
WM treatment has improved substantially with BTK inhibitors, but the mechanisms behind sensitivity and resistance are still not fully understood. Traditional testing on bulk tumor samples can miss rare subclones and dynamic immune changes. By analyzing sequential bone marrow samples from the same patients over many treatment cycles, the researchers were able to map clonal evolution in real time and identify cellular features linked to response or resistance.
The study also aimed to develop a practical biomarker that could help predict, at baseline, which patients were more likely to respond to ibrutinib and which were at risk for resistance.
How the study was done
Seventeen treatment-naïve patients with WM were enrolled. Across the course of therapy, 74 bone marrow aspirates were collected from baseline through 48 treatment cycles. The samples were analyzed using single-cell multiomics, allowing the team to study both tumor cells and immune cells in the same dataset.
Bone marrow cells were mainly divided into two major compartments:
1. Malignant B-cell/plasma cell populations
2. T-cell populations
The investigators then tracked how tumor clones changed over time and how those changes matched clinical outcomes. They also compared gene-expression programs in resistant and sensitive tumor cells to identify candidate biomarkers and possible therapeutic targets.
Three patterns of tumor evolution
The most important finding was that malignant B cells and plasma cells followed three distinct longitudinal patterns during ibrutinib treatment:
1. Evolution: early contraction of the dominant clone followed by later regrowth and increasing genomic complexity
2. Devolution: early clone expansion followed by later contraction and genomic simplification
3. No evolution: a stable clonal architecture over time
These patterns were not just biologic curiosities. They carried clinical meaning.
Patients whose tumors showed the evolution pattern were much more likely to experience disease progression. In contrast, the devolution pattern was associated with durable clinical response. In other words, early shrinkage of a clone did not guarantee long-term control if the cancer later adapted and expanded again. The no-evolution group had relatively stable disease biology, but the clinical course still needed to be interpreted in context.
What clonal evolution tells us about resistance
The evolution pattern suggests that ibrutinib can initially suppress the dominant malignant clone, but a resistant subclone may survive, expand, and acquire additional genomic alterations over time. This increasing genomic complexity may help the tumor bypass BTK inhibition.
By contrast, devolution appears to reflect a more sustained suppression of the malignant population, with fewer signs of genetic adaptation. This may represent a state in which ibrutinib remains effective enough to keep the disease under control over a longer period.
These findings reinforce an important principle in cancer biology: treatment response is not static. Even when a patient appears to respond early, resistant subclones may emerge later. That is why longitudinal monitoring can be so valuable in chronic blood cancers like WM.
The WIP score: a predictive tool for treatment response
To better predict response before treatment starts, the researchers used transcriptomic data from resistant clones to build and validate the Waldenström ibrutinib prediction, or WIP, score. This biomarker was designed to estimate the likelihood of response at baseline.
The WIP score performed as a predictive signature for ibrutinib sensitivity. In practical terms, it may eventually help clinicians identify patients who are more likely to benefit from ibrutinib alone and those who may need closer monitoring or alternative strategies.
Among the genes in the WIP signature, LYN stood out as a key regulator. LYN is a Src-family kinase involved in B-cell receptor signaling and cell survival pathways. When LYN was knocked down or inhibited in WM cells, the cells became more sensitive to ibrutinib. This suggests that combining BTK inhibition with strategies that target LYN could be a rational approach to overcoming resistance.
Immune-cell changes: T-cell dysfunction alongside tumor evolution
The study did not focus only on tumor cells. It also revealed important changes in the immune microenvironment, especially among T cells.
In patients with progressive disease, GZMB+ CD8+ effector-memory T cells expanded after treatment. At first glance, an expansion of cytotoxic T cells might seem beneficial. However, these cells showed signs of dysfunction rather than effective anti-tumor activity. They had persistently impaired cytotoxic programs, including reduced expression of GNLY, a molecule associated with killing target cells.
These T cells also displayed a dedifferentiated, memory-like state, increased expression of PDCD1, which is a marker associated with T-cell exhaustion, and reduced T-cell receptor diversity. Together, these features suggest that the immune response was not fully functional and may have been unable to keep pace with tumor evolution.
In patients who progressed, this dysfunctional T-cell pattern coexisted with tumor clonal expansion. The simultaneous presence of adapting tumor cells and exhausted or poorly effective T cells may help explain why some patients do not maintain durable control on ibrutinib.
Clinical implications
This study has several important implications for WM care.
First, it shows that resistance to ibrutinib is not driven by a single mechanism. Instead, resistance can arise from both tumor-intrinsic changes, such as clonal evolution and genomic complexity, and tumor-extrinsic factors, such as an impaired immune environment.
Second, the WIP score offers a potential biomarker to help predict response before therapy begins. Biomarkers are especially valuable in WM because treatment choices often need to balance efficacy, durability, toxicity, and the need for long-term disease control.
Third, the identification of LYN as a candidate resistance node points toward combination therapy. While ibrutinib remains an important therapy, future regimens may need to pair BTK inhibition with agents that block complementary survival signals.
Fourth, the immune findings raise the possibility that T-cell dysfunction contributes to limited treatment durability. This could eventually inform strategies that combine targeted therapy with immune-modulating approaches, although such strategies would require careful clinical testing.
How this fits into current WM treatment
Ibrutinib is one of the established treatments for WM, along with other BTK inhibitors and other approaches such as rituximab-based regimens, proteasome inhibitors, and, in selected cases, chemoimmunotherapy. The choice of treatment depends on disease burden, symptoms, patient age, comorbidities, and prior therapy.
This study does not replace current treatment standards, but it adds an important layer of understanding. It suggests that patient selection and resistance monitoring may be just as important as drug choice. In the future, clinicians may use genomic and transcriptomic signatures to personalize therapy and intervene earlier when resistance begins to emerge.
Limitations
As with any translational study, there are limitations. The patient number was relatively small, reflecting the rarity of WM and the complexity of repeated longitudinal sampling. Also, while the findings are biologically compelling, some of the biomarker and combination-therapy concepts will need validation in larger independent cohorts and clinical trials before they can be adopted routinely.
In addition, the study used bone marrow samples, which provide a rich view of the disease but may not fully capture disease behavior in all body compartments. Still, the depth of single-cell analysis makes the findings especially informative.
Bottom line
This study provides a high-resolution picture of how WM responds to ibrutinib over time. It identifies three tumor evolutionary trajectories, links one of them strongly to progression and another to durable benefit, and introduces the WIP score as a promising predictor of response. It also shows that resistant disease is shaped not only by tumor genetics but also by dysfunctional T-cell states.
Taken together, these findings move WM closer to a more personalized treatment model in which tumor evolution, immune status, and predictive biomarkers guide therapy selection and combination strategies.
